Dynavax Technologies Corporation (DVAX)

NASDAQ
14.500
+0.440(+3.13%)
  • Volume:
    625,318
  • Day's Range:
    14.080 - 14.610
  • 52 wk Range:
    7.260 - 21.390

DVAX Overview

Prev. Close
14.06
Day's Range
14.08-14.61
Revenue
470.1M
Open
14.09
52 wk Range
7.26-21.39
EPS
0.52
Volume
625,318
Market Cap
1.83B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,937,297
P/E Ratio
27.05
Beta
1.29
1-Year Change
48%
Shares Outstanding
126,312,469
Next Earnings Date
Aug 10, 2022
What is your sentiment on Dynavax?
or
Vote to see community's results!

Dynavax Technologies Corporation News

  • Dynavax Misses Q1 EPS by 2c
    • ByInvesting.com-

    Dynavax (NASDAQ:DVAX) reported Q1 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $114 million versus the consensus estimate of...

  • Valneva Shares Off 12% On Share Offering News
    • ByInvesting.com-

    by David Wagner and Daniel ShvartsmanInvesting.com -- French pharmaceutical company Valneva SE ADR (NASDAQ:VALN) shares dropped 12% after announcing a share offering.The...

Dynavax Technologies Corporation Analysis

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation Company Profile

Employees
245

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsSellStrong BuyStrong BuyStrong BuyBuy
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Buy
  • 🤣💥🚀💫🤣
    0
    • Buy the dips
      0
      • More than 400million vaccine doses via Clover Pharma sold to Cepi, More to come from Valneva, WHO will buy more....stable vaccine and Dynavax Adjuvant stable at room temperature for a month or more.
        0
        • totally rely on Heplisav-B for hepatitis B now.
          0
          • https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19
            0
            • no more story for covid 19. run. personal opinion
              0
              • run.seems oledi earn. dun be surprise if .....another -15% dumping on monday.
                0
                • as predicted.20
                  0
                  • Valneva
                    1
                    • $16+ today
                      1